Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 4-week study of Allegra dry syrup in pediatric atopic dermatitis
2017-000251-74Phase 3
- Sponsor
- Sanofi
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fexofenadine in atopic dermatitis (AD), sponsored by Sanofi. Primary endpoints: Safety (4-week period) and Long-term safety (12-week period).
02
Drugs
fexofenadine
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-000251-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000251-74.